Navigating Phase 3 Clinical Trials for Sepsis-Associated Acute Kidney Injury to Break the Mould in AKI

Time: 2:30 pm
day: Seminar Day


  • From identifying patients to defining endpoints: analyzing a 650-patient phase 3 trial in AKI
  • Surmounting 28-day mortality data and composite endpoints
  • Redefining a new path to approval: what does the future of AKI drug development look like?